A citation-based method for searching scientific literature

Alexander Chi, Xia He, Lin Hou, Nam P Nguyen, Guangying Zhu, Robert B Cameron, Jay M Lee. Cancers (Basel) 2021
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Immune Landscape of Cancer.
Vésteinn Thorsson, David L Gibbs, Scott D Brown, Denise Wolf, Dante S Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, Galen F Gao, Christopher L Plaisier, James A Eddy,[...]. Immunity 2018
100

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O Butler, Mary L Disis, Jérôme Galon, Leif G Hakansson, Brent A Hanks, Vaios Karanikas, Samir N Khleif,[...]. J Immunother Cancer 2017
121
50

Cold Tumors: A Therapeutic Challenge for Immunotherapy.
Paola Bonaventura, Tala Shekarian, Vincent Alcazer, Jenny Valladeau-Guilemond, Sandrine Valsesia-Wittmann, Sebastian Amigorena, Christophe Caux, Stéphane Depil. Front Immunol 2019
259
50

Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Jingjing Liu, Shuang Li, Shuang Zhang, Ying Liu, Lixia Ma, Jing Zhu, Ying Xin, Ying Wang, Changliang Yang, Ying Cheng. J Clin Lab Anal 2019
45
50

License to kill: microsatellite instability and immune contexture.
Pauline Maby, Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon. Oncoimmunology 2021
2
50

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Sonja Althammer, Tze Heng Tan, Andreas Spitzmüller, Lorenz Rognoni, Tobias Wiestler, Thomas Herz, Moritz Widmaier, Marlon C Rebelatto, Helene Kaplon, Diane Damotte,[...]. J Immunother Cancer 2019
36
50

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.
Miranda L Broz, Mikhail Binnewies, Bijan Boldajipour, Amanda E Nelson, Joshua L Pollack, David J Erle, Andrea Barczak, Michael D Rosenblum, Adil Daud, Diane L Barber,[...]. Cancer Cell 2014
508
50

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth. Science 2011
50


Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei. Cancer 2020
61
50

Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.
Filippo Galli, Jesus Vera Aguilera, Belinda Palermo, Svetomir N Markovic, Paola Nisticò, Alberto Signore. J Exp Clin Cancer Res 2020
29
50

Macrophage polarity in cancer: A review.
Masoud Najafi, Nasser Hashemi Goradel, Bagher Farhood, Eniseh Salehi, Maryam Shabani Nashtaei, Neda Khanlarkhani, Zahra Khezri, Jamal Majidpoor, Morteza Abouzaripour, Mohsen Habibi,[...]. J Cell Biochem 2019
133
50

The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier.
Sara I Pai, Alessandra Cesano, Francesco M Marincola. Cancer Treat Res 2020
12
50

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Weiyi Peng, Jie Qing Chen, Chengwen Liu, Shruti Malu, Caitlin Creasy, Michael T Tetzlaff, Chunyu Xu, Jodi A McKenzie, Chunlei Zhang, Xiaoxuan Liang,[...]. Cancer Discov 2016
730
50

Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors.
Yu Zhang, Xin-Yuan Guan, Peng Jiang. Front Immunol 2020
14
50

Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice.
Sharmilla Devi Jayasingam, Marimuthu Citartan, Thean Hock Thang, Anani Aila Mat Zin, Kai Cheen Ang, Ewe Seng Ch'ng. Front Oncol 2020
120
50

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.
Patrick H Lizotte, Elena V Ivanova, Mark M Awad, Robert E Jones, Lauren Keogh, Hongye Liu, Ruben Dries, Christina Almonte, Grit S Herter-Sprie, Abigail Santos,[...]. JCI Insight 2016
79
50

Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.
Christiane Kümpers, Mladen Jokic, Ozan Haase, Anne Offermann, Wenzel Vogel, Victoria Grätz, Ewan A Langan, Sven Perner, Patrick Terheyden. Front Med (Lausanne) 2019
21
50

Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
Ju Yang, Jing Yan, Baorui Liu. Front Immunol 2018
183
50

Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Gautam Kishore Valecha, Adarsh Vennepureddy, Uroosa Ibrahim, Firas Safa, Bachar Samra, Jean Paul Atallah. Expert Rev Anticancer Ther 2017
25
50

Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer.
Nora Ness, Sigve Andersen, Andrej Valkov, Yngve Nordby, Tom Donnem, Samer Al-Saad, Lill-Tove Busund, Roy M Bremnes, Elin Richardsen. Prostate 2014
58
50

Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.
Mikko Mella, Joonas H Kauppila, Peeter Karihtala, Petri Lehenkari, Arja Jukkola-Vuorinen, Ylermi Soini, Päivi Auvinen, Markku H Vaarala, Hanna Ronkainen, Saila Kauppila,[...]. Oncoimmunology 2015
28
50

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
Elisabeth Brambilla, Gwénaël Le Teuff, Sophie Marguet, Sylvie Lantuejoul, Ariane Dunant, Stephen Graziano, Robert Pirker, Jean-Yves Douillard, Thierry Le Chevalier, Martin Filipits,[...]. J Clin Oncol 2016
176
50


Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Xiaozhou Fan, Sergio A Quezada, Manuel A Sepulveda, Padmanee Sharma, James P Allison. J Exp Med 2014
168
50

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures.
Nicolas Gestermann, Damien Saugy, Christophe Martignier, Laure Tillé, Silvia A Fuertes Marraco, Markus Zettl, Iñigo Tirapu, Daniel E Speiser, Grégory Verdeil. Oncoimmunology 2020
9
50

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Osamu Kawai, Genichiro Ishii, Kaoru Kubota, Yukinori Murata, Yoichi Naito, Tetsuya Mizuno, Keiju Aokage, Nagahiro Saijo, Yutaka Nishiwaki, Akihiko Gemma,[...]. Cancer 2008
264
50

Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses.
Donglai Chen, Yifei Wang, Xi Zhang, Qifeng Ding, Xiaofan Wang, Yuhang Xue, Wei Wang, Yiming Mao, Chang Chen, Yongbing Chen. Front Oncol 2021
3
50

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.
Daniela Bruni, Helen K Angell, Jérôme Galon. Nat Rev Cancer 2020
167
50

Interferon-γ: teammate or opponent in the tumour microenvironment?
Angela M Gocher, Creg J Workman, Dario A A Vignali. Nat Rev Immunol 2021
7
50


Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
Jérôme Galon, Bernhard Mlecnik, Gabriela Bindea, Helen K Angell, Anne Berger, Christine Lagorce, Alessandro Lugli, Inti Zlobec, Arndt Hartmann, Carlo Bifulco,[...]. J Pathol 2014
801
50

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Katerina Ancevski Hunter, Mark A Socinski, Liza C Villaruz. Mol Diagn Ther 2018
84
50

Blood tumor mutational burden: are we ready for clinical implementation?
Claude Van Campenhout, Bárbara Meléndez, Myriam Remmelink, Isabelle Salmon, Nicky D'Haene. J Thorac Dis 2019
2
50

Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Tomonari Kinoshita, Chie Kudo-Saito, Reiko Muramatsu, Tomonobu Fujita, Miyuki Saito, Haruna Nagumo, Toshiharu Sakurai, Shinobu Noji, Emi Takahata, Tomonori Yaguchi,[...]. Eur J Cancer 2017
42
50

Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
Hernani Gil-Julio, Francisco Perea, Antonio Rodriguez-Nicolas, Jose Manuel Cozar, Amanda Rocío González-Ramirez, Angel Concha, Federico Garrido, Natalia Aptsiauri, Francisco Ruiz-Cabello. Int J Mol Sci 2021
1
100

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
Rebekka Weber, Viktor Fleming, Xiaoying Hu, Vasyl Nagibin, Christopher Groth, Peter Altevogt, Jochen Utikal, Viktor Umansky. Front Immunol 2018
214
50

Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies, Edward W Roberts, Kelly Kersten, Vincent Chan, Douglas F Fearon, Miriam Merad, Lisa M Coussens, Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Catherine C Hedrick,[...]. Nat Med 2018
50

The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.
Åsa Kristina Öjlert, Ann Rita Halvorsen, Daniel Nebdal, Marius Lund-Iversen, Steinar Solberg, Odd Terje Brustugun, Ole Christian Lingjaerde, Åslaug Helland. Mol Oncol 2019
27
50

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo. Mol Cancer 2019
255
50

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
David R Gandara, Sarah M Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine Malboeuf,[...]. Nat Med 2018
507
50

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz, Jonathan J Havel, Vladimir Makarov, Alexis Desrichard, Walter J Urba, Jennifer S Sims, F Stephen Hodi, Salvador Martín-Algarra, Rajarsi Mandal, William H Sharfman,[...]. Cell 2017
674
50

Emerging biomarkers for immune checkpoint inhibition in lung cancer.
George Cyriac, Leena Gandhi. Semin Cancer Biol 2018
47
50

Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma.
Hanne Krogh Jensen, Frede Donskov, Marianne Nordsmark, Niels Marcussen, Hans von der Maase. Clin Cancer Res 2009
71
50

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
Albrecht Stenzinger, Jeffrey D Allen, Jörg Maas, Mark D Stewart, Diana M Merino, Madison M Wempe, Manfred Dietel. Genes Chromosomes Cancer 2019
81
50


Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Kristian M Hargadon, Coleman E Johnson, Corey J Williams. Int Immunopharmacol 2018
391
50

Biomarkers for Immunotherapy: Current Developments and Challenges.
Kristen R Spencer, Jianfeng Wang, Ann W Silk, Shridar Ganesan, Howard L Kaufman, Janice M Mehnert. Am Soc Clin Oncol Educ Book 2016
51
50

The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer.
Roy M Bremnes, Lill-Tove Busund, Thomas L Kilvær, Sigve Andersen, Elin Richardsen, Erna Elise Paulsen, Sigurd Hald, Mehrdad Rakaee Khanehkenari, Wendy A Cooper, Steven C Kao,[...]. J Thorac Oncol 2016
195
50

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.
J Galon, B A Fox, C B Bifulco, G Masucci, T Rau, G Botti, F M Marincola, G Ciliberto, F Pages, P A Ascierto,[...]. J Transl Med 2016
96
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.